Physician profile
James A Turecki
NPI 1023081627
$4,258.40
in general payments reported to CMS, 2019-2025
56 companies · $401 in 2025
The $401 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $599 · 2020: $279 · 2021: $513 · 2022: $842 · 2023: $792 · 2024: $833 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,002 · Education: $23.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,001.85 |
| Education | $23.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $678.49 | 2021-2022 | |
| Astellas Pharma US INC | $431.22 | 2019-2024 | Xtandi |
| Axonics, INC. | $317.73 | 2023-2024 | Bulkamid, Axonics |
| Medtronic, INC. | $252.26 | 2022-2024 | Interstim |
| 180 Medical, INC. | $207.05 | 2021-2025 | Gentlecath, Gentlecath Glide, Speedicath |
| Pfizer INC. | $204.67 | 2019-2024 | |
| Abbvie INC. | $197.20 | 2020-2024 | Botox |
| Boston Scientific Corporation | $134.81 | 2022-2025 | Axonics |
| Medtronic USA, INC. | $130.85 | 2019 | |
| Ambu INC. | $103.48 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.41 | 2022-2025 | |
| Myriad Genetic Laboratories, INC. | $86.79 | 2024 | Prolaris |
| Urogen Pharma, INC. | $81.13 | 2022-2024 | |
| Janssen Biotech, INC. | $80.40 | 2022-2025 | Erleada |
| Endo USA, INC. | $72.06 | 2025 | Aveed, Xiaflex |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Turecki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.